AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Geron Corporation (GERN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

2.63

0.09 (3.54%)

At close: Feb 20, 2025, 3:59 PM

2.64

0.19%

After-hours: Feb 20, 2025, 06:09 PM EST

undefined% (undefined)

Bid	2.62
Market Cap	1.59B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.32
PE Ratio (ttm)	-8.23
Forward PE	n/a
Analyst	Buy

Ask	2.64
Volume	8,368,606
Avg. Volume (20D)	11,116,900
Open	2.53
Previous Close	2.54
Day's Range	2.50 - 2.65
52-Week Range	1.64 - 5.34
Beta	undefined

About GERN

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes a...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 31, 1996

Employees 141

Stock Exchange NASDAQ

Ticker Symbol GERN

Website https://www.geron.com

Full Company Profile

Analyst Forecast

According to 11 analyst ratings, the average rating for GERN stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 165.65% from the latest price.

Buy 90.91%

Hold 9.09%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Geron Corporation is scheduled to release its earnings on Feb 26, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

7 months ago

-7.14%

Geron shares are trading lower after the company a... Unlock content with Pro Subscription

7 months ago

-1.28%

Geron shares are trading lower after the company announced the departure of CCO Anil Kapur.

News

1 day ago · businesswire.com

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 180,000 ...

2 weeks ago · seekingalpha.com

Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch

GERN's Rytelo, approved in mid-2024, shows promising initial sales, with Q3'24 net revenues at $28.2M, and preliminary Q4'24 net revenues of $45M-$46M. Despite some market exclusivity concerns, GERN s...

1 month ago · seekingalpha.com

Geron: Positive IMpactMF Trial Could Possibly Lead To Doubling Of RYTELO Sales

Geron Corporation's RYTELO received FDA approval for Low-Risk Myelodysplastic Syndrome and is awaiting European Medicines Agency approval as well, which might help to boost sales. Geron reported $28.2...

1 month ago · zacks.com

Geron Stock Rallies More Than 60% in a Year: Here's Why

FDA's approval of GERN's Rytelo (imetelstat) for treating low- to intermediate-1 risk MDS drives the stock 61.1% higher in the past year.

2 months ago · businesswire.com

Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that...

2 months ago · businesswire.com

Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to participate i...

3 months ago · seekingalpha.com

Geron: A Strong Launch And Financial Deals Make It Attractive

Geron exceeded expectations with $28.2mn in Q1 revenue, surpassing analyst estimates and showcasing strong physician feedback and market potential for imetelstat. Analysts are bullish, with H.C. Wainw...